Trial results presented at the annual meeting of the American Society of Hematology showed decided advantages of Hympavzi (mastacimab) over on-demand treatment with bypassing agents.
Mark Kestner
Advertisement
Mark Kestner, MD is Chief Innovation Officer of MediGuru. He has extensive executive leadership experience in the military, university systems, integrated delivery systems and particularly in community-based healthcare systems.
Articles by Mark Kestner
Despite advances in medical science and technology, our healthcare system doesn’t always translate knowledge into practice. All too often, this leaves healthcare providers questioning the key business decisions that impact patient care. What caregivers need is a model for applying new technology safely and appropriately. Thankfully, such a model exists: the High Reliability Organization (HRO) model.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Immune system targets single beta cells before Type 1 diabetes symptoms show
3
Winter exposes how closely eczema, asthma and allergies are linked
4
Novel tracer can identify lung lesions in those with connective tissue diseases
5